Relmada Therapeutics, Inc. (RLMD)


+0.06 (+2.04%)
Symbol RLMD
Price $3
Beta 0.078
Volume Avg. 0.15M
Market Cap 90.298M
Shares () -
52 Week Range 1.81-38.68
1y Target Est -
DCF Unlevered RLMD DCF ->
DCF Levered RLMD LDCF ->
ROE -93.51% Strong Sell
ROA -104.13% Strong Sell
Operating Margin -
Debt / Equity -
P/E -0.69
P/B 0.81 Buy


Consensus EPS

Upgrades & Downgrades

Latest RLMD news

Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
NASDAQ Global Select

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.